SG11202102400PA - Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain - Google Patents

Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Info

Publication number
SG11202102400PA
SG11202102400PA SG11202102400PA SG11202102400PA SG11202102400PA SG 11202102400P A SG11202102400P A SG 11202102400PA SG 11202102400P A SG11202102400P A SG 11202102400PA SG 11202102400P A SG11202102400P A SG 11202102400PA SG 11202102400P A SG11202102400P A SG 11202102400PA
Authority
SG
Singapore
Prior art keywords
treatment
pharmaceutical compositions
compositions suitable
joint pain
articular delivery
Prior art date
Application number
SG11202102400PA
Inventor
Yun-Long Tseng
Sheue-Fang Shih
Po-Chun Chang
Lo Chang
Original Assignee
Tlc Biopharmaceuticals Inc
Taiwan Liposome Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tlc Biopharmaceuticals Inc, Taiwan Liposome Co Ltd filed Critical Tlc Biopharmaceuticals Inc
Publication of SG11202102400PA publication Critical patent/SG11202102400PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202102400PA 2018-09-16 2019-09-16 Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain SG11202102400PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731941P 2018-09-16 2018-09-16
PCT/US2019/051247 WO2020056399A1 (en) 2018-09-16 2019-09-16 Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Publications (1)

Publication Number Publication Date
SG11202102400PA true SG11202102400PA (en) 2021-04-29

Family

ID=68084954

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102400PA SG11202102400PA (en) 2018-09-16 2019-09-16 Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Country Status (13)

Country Link
US (1) US20210338688A1 (en)
EP (1) EP3849522A1 (en)
JP (1) JP2022500364A (en)
KR (1) KR20210060559A (en)
CN (1) CN112702993A (en)
AU (1) AU2019339528A1 (en)
BR (1) BR112021004880A2 (en)
CA (1) CA3112234A1 (en)
CL (1) CL2021000627A1 (en)
IL (1) IL281513A (en)
MX (1) MX2021003030A (en)
SG (1) SG11202102400PA (en)
WO (1) WO2020056399A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230048066A (en) 2020-08-05 2023-04-10 티엘씨 바이오파머슈티컬즈 인코포레이티드 Pharmaceutical compositions of intra-articular corticosteroids for pain control

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
EP1371362A1 (en) * 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
WO2014008469A2 (en) * 2012-07-05 2014-01-09 Taiwan Liposome Company, Ltd. Methods of treating arthritis

Also Published As

Publication number Publication date
BR112021004880A2 (en) 2021-06-01
WO2020056399A1 (en) 2020-03-19
MX2021003030A (en) 2021-05-27
KR20210060559A (en) 2021-05-26
JP2022500364A (en) 2022-01-04
CL2021000627A1 (en) 2021-09-10
US20210338688A1 (en) 2021-11-04
AU2019339528A1 (en) 2021-04-15
EP3849522A1 (en) 2021-07-21
IL281513A (en) 2021-04-29
TW202023569A (en) 2020-07-01
CN112702993A (en) 2021-04-23
CA3112234A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
IL283840A (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
IL253195B (en) Pharmaceutical compositions comprising synthetic glycans for use in treatment of gastrointestinal diseases and methods of preparing them"
IL270812B1 (en) Solid compositions for oral administration comprising semaglutide and dapagliflozin and their use in medicine
EP3813853A4 (en) Compositions for drug delivery and methods of use thereof
IL266519A (en) Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash
IL274578A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
IL266623A (en) Pharmaceutical composition for use in the therapeutic treatment of cancer and complications of cancer
EP3753557A4 (en) Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
EP4183391A4 (en) Pharmaceutical composition and use thereof
GB201714430D0 (en) Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
IL311331A (en) Pharmaceutical composition and use thereof
IL283522A (en) Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
IL281513A (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
IL280550A (en) A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
IL272495A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
PT3937948T (en) Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases
TWI843751B (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
IL271013B (en) Substituted isoindole allosteric egfr inhibitors,pharmaceutical compositions comprising them and their use in the therapeutic and/or prophylactic treatment of cancer
EP3749332A4 (en) Compositions and their use in the treatment of endometriosis and pain
IL271596A (en) Compositions for drug delivery and methods of use thereof
EP3856148A4 (en) Pharmaceutical formulation containing a selenitetriglyceride and a cytostatic for use in treatment of tumour
EP3838270A4 (en) Synergistic pharmaceutical composition comprising aceclofenac and betamethasone for the treatment of pain in localised forms of rheumatic illnesses
GB201817346D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of diseases
PL3768246T3 (en) Saposin c pharmaceutical compositions and their use in treating cancer
EP4051249C0 (en) Pharmaceutical composition comprising mitotane for oral administration for use in the treatment of adrenocortical carcinoma and cushing-syndrome